Working… Menu

Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00286936
Recruitment Status : Terminated (Slow inclusion resulting in premature termination due to logistics)
First Posted : February 6, 2006
Last Update Posted : August 30, 2011
IMK Fonden
Information provided by:
Hvidovre University Hospital

Brief Summary:
To examine the influence of regular hypnotic therapy on the incidence of delirium after hip fracture surgery

Condition or disease Intervention/treatment Phase
Hip Fracture Delirium Drug: Zolpidem Phase 4

Detailed Description:
Delirium is prevalent after hip fracture surgery. Delirium has been linked to postoperative sleep disturbances. Zolpidem is a non-benzodiazepine hypnotic that preserves REM sleep. The present study investigates the incidence of delirium in hip fracture patients randomized to Zolpidem treatment 5 mg vs placebo in the perioperative phase.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo
Study Start Date : February 2004
Actual Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Incidence and severity of postoperative delirium

Secondary Outcome Measures :
  1. Sleep quality
  2. mobilization
  3. loss of functional ability
  4. length of stay
  5. sedation
  6. nocturnal nursing events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary hip fracture, no substance abuse, no regular opioid, corticosteroid or benzodiazepine therapy, hepatic insufficiency, myastenia gravis, allergies to drug components

Exclusion Criteria:

  • Severe respiratory insufficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00286936

Layout table for location information
Hvidovre University Hospital
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
IMK Fonden
Layout table for investigator information
Study Director: Nicolai B Foss, MD Hvidovre University Hospital
Layout table for additonal information Identifier: NCT00286936    
Other Study ID Numbers: HHSG-RCT-05
First Posted: February 6, 2006    Key Record Dates
Last Update Posted: August 30, 2011
Last Verified: September 2006
Keywords provided by Hvidovre University Hospital:
Hip fracture
sleep disturbance
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Hip Fractures
Wounds and Injuries
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Femoral Fractures
Hip Injuries
Leg Injuries
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action